DBV patch-based peanut therapy reports long-term desensitization results
Epicutaneous immunotherapy for peanut allergy in children showed long-term efficacy and safety, with 68.2% tolerating full food challenges after three years.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.